COVID-19 trials registries data warehouse

http://en.irct.ir/trial/49657

Dr. Teamur Aghamolaei

research@hums.ac.ir

2020-08-17

Completed

RCT

Randomized

Parallel

Blind label

single-center

Treatment

All COVID-19 patients whose disease has been confirmed by the PCR test for SARS-Cov-2. Signing the written consent of the study participant.

All Immunocompromised patients End stage renal disease Moderate renal insufficiency (creatinine clearance 30-50 mL/min) stage 4 sever chronic kidney disease requiring dialysis (i.e creatinine clearance <30 mL/min) History of hepatic disease History of hepatitis C infection History of alcoholism G-6-PD (glucose-6-phosphate dehydrogenase deficiency) ALT/AST >5 times the upper limit of normal. History of or evidence of QT prolongation on ECG examination History of psoriasis History of porphyria Pregnancy Use of oral contraceptive pills (OCP) Concomitant use of Dasatinib Concomitant use of Neratinib Concomitant use of Ozanimod Concomitant use of Pazopanib Concomitant use of Rilpivirine Concomitant use of Siponimod Concomitant use of Tizanidine Allergy to any study medication

2

Bandare-abbas University of Medical Sciences

0

100

Iran

No restriction on type of patients

0: No restriction on type of patients

20

Respiratory rate Oxygen saturation state Lung infiltration status Lactate Dehydrogenase(LDH) level's C-reactive protein(CRP) level's Lymphocyte count Platelet count

Phase 3

[{"arm_notes": "", "treatment_id": 503, "treatment_name": "Famotidine", "treatment_type": "Others pharmacological treatment", "pharmacological_treatment": "Pharmacological treatment"}, {"arm_notes": "", "treatment_id": 2187, "treatment_name": "Placebo", "treatment_type": "Placebo", "pharmacological_treatment": "Placebo"}]